Allogene Therapeutics (ALLO) Non-Current Deferred Tax Liability (2018 - 2021)

Allogene Therapeutics (ALLO) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $68000.0 in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Deferred Tax Liability changed N/A year-over-year to $68000.0; the trailing twelve-month figure through Dec 2021 stood at $68000.0 (changed N/A YoY), and the FY2021 full-year result was $68000.0, changed N/A from the prior year.
• Non-Current Deferred Tax Liability retreated to $68000.0 in Q4 2021, from $361000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $531000.0 in Q4 2018 to a low of $68000.0 in Q4 2021.
• A 3-year average of $320000.0 and a median of $361000.0 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• Peak annual rise in Non-Current Deferred Tax Liability reached 32.02% in 2019, while the deepest fall reached 32.02% in 2019.
• Tracing ALLO's Non-Current Deferred Tax Liability over 3 years: stood at $531000.0 in 2018, then sank by 32.02% to $361000.0 in 2019, then tumbled by 81.16% to $68000.0 in 2021.
• Business Quant data shows ALLO's Non-Current Deferred Tax Liability at $68000.0 in Q4 2021, $361000.0 in Q4 2019, and $531000.0 in Q4 2018.